Effect of vericiguat on cardiovascular outcomes in patients with heart failure with and without diabetes: Insights from the VICTORIA trial

被引：0
|
作者：
Khan, S. [1 ]
Butler, J. [2 ]
Young, R. [1 ]
Lewis, B. S. [3 ]
Escobedo, J. [4 ]
Refsgaard, J. [5 ]
Reyes, E. [6 ]
Roessig, L. [7 ]
Blaustein, R. O. [8 ]
Lam, C. S. P. [9 ]
Voors, A. A. [10 ]
Ponikowski, P. [11 ]
Anstrom, K. J. [1 ]
Armstrong, P. [12 ]
机构：
[1] Duke Clin Res Inst, Durham, NC USA
[2] Baylor Univ, Med Ctr, Dallas, TX USA
[3] Lady Davis Carmel Med Ctr, Haifa, Israel
[4] Univ Nacl Autonoma Mexico, Mexico City, DF, Mexico
[5] Reg Hosp Viborg, Viborg, Denmark
[6] Philippine Gen Hosp, Manila, Philippines
[7] Bayer AG, Wuppertal, Germany
[8] Merck & Co Inc, Rahway, NJ USA
[9] Duke Natl Univ Singapore, Natl Heart Ctr Singapore, Singapore, Singapore
[10] Univ Med Ctr Groningen, Groningen, Netherlands
[11] Wroclaw Med Univ, Wroclaw, Poland
[12] Univ Alberta, Edmonton, AB, Canada
来源：
EUROPEAN HEART JOURNAL | 2023年 / 44卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: insights from the CANVAS Program and CREDENCE trial
    Sharma, A. Abhinav
    Neuen, B. L.
    Fletcher, R. A.
    Slee, A.
    Rapattoni, W.
    Ang, F. G.
    Arnott, C.
    Levin, A.
    Verma, S.
    Perkovic, V.
    Mahaffey, K. W.
    EUROPEAN JOURNAL OF HEART FAILURE, 2023, 25 : 177 - 178
  • [32] Timing of statistical benefit of canagliflozin in patients with type 2 diabetes for cardiovascular and heart failure outcomes: Insights from the CANVAS Program and CREDENCE trial
    Sharma, Abhinav
    Marques, Pedro
    Neuen, Brendon L.
    Fletcher, Robert A.
    Slee, April
    Rapattoni, Wally
    Ang, Fernando G.
    Arnott, Clare
    Levin, Adeera
    Verma, Subodh
    Perkovic, Vlado
    Mahaffey, Kenneth W.
    DIABETES OBESITY & METABOLISM, 2024, 26 (02): : 758 - 762
  • [33] Cost-Effectiveness of Vericiguat in Patients With Heart Failure With Reduced Ejection Fraction: The VICTORIA Randomized Clinical Trial
    Chew, Derek S.
    Li, Yanhong
    Bigelow, Robert
    Cowper, Patricia A.
    Anstrom, Kevin J.
    Daniels, Melanie R.
    Davidson-Ray, Linda
    Hernandez, Adrian F.
    O'Connor, Christopher M.
    Armstrong, Paul W.
    Mark, Daniel B.
    CIRCULATION, 2023, 148 (14) : 1087 - 1098
  • [34] Changes in natriuretic peptide and effects of vericiguat in worsening heart failure with reduced ejection fraction: Insights from VICTORIA (VerICiguaT Global Study in Subjects with HFrEF)
    Ezekowitz, J.
    Zheng, Y.
    Lund, L.
    Zhang, J.
    Troughton, R.
    Westerhout, C.
    Blaustein, R.
    Butler, J.
    Hernandez, A. F.
    Lam, C. S. P.
    Pieske, B.
    Roessig, L.
    Ponikowski, P.
    O'connor, C. M.
    Armstrong, P. W. Paul Wayne
    EUROPEAN JOURNAL OF HEART FAILURE, 2021, 23 : 50 - 50
  • [35] A Systematic Review of the Effect of Vericiguat on Patients with Heart Failure
    Sahana, Urjosee
    Wehland, Markus
    Simonsen, Ulf
    Schulz, Herbert
    Grimm, Daniela
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2023, 24 (14)
  • [36] The effect of diabetes on outcomes of patients with advanced-heart failure in the BEST trial
    Domanski, M
    Krause-Steinrauf, H
    Deedwania, P
    Follmann, D
    Ghali, JK
    Gilbert, E
    Haffner, S
    Katz, R
    Lindenfeld, J
    Lowes, BD
    Martin, W
    McGrew, F
    Bristow, MR
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 42 (05) : 914 - 922
  • [37] Effect of Empagliflozin on Cardiovascular and Renal Outcomes in Patients With Heart Failure by Baseline Diabetes Status Results From the EMPEROR-Reduced Trial
    Anker, Stefan D.
    Butler, Javed
    Filippatos, Gerasimos
    Khan, Muhammad Shahzeb
    Marx, Nikolaus
    Lam, Carolyn S. P.
    Schnaidt, Sven
    Ofstad, Anne Pernille
    Brueckmann, Martina
    Jamal, Waheed
    Bocchi, Edimar A.
    Ponikowski, Piotr
    Perrone, Sergio, V
    Januzzi, James L.
    Verma, Subodh
    Boehm, Michael
    Ferreira, Joao Pedro
    Pocock, Stuart J.
    Zannad, Faiez
    Packer, Milton
    CIRCULATION, 2021, 143 (04) : 337 - 349
  • [38] Effect of liraglutide on cardiovascular outcomes in patients with or without prior heart failure history in LEADER
    Saevereid, H. A.
    Husain, M.
    Bain, S. C.
    Mann, J. F. E.
    Nauck, M. A.
    Poulter, N.
    Goldman, B.
    Thomsen, A. B.
    Marso, S.
    DIABETOLOGIA, 2018, 61 : S564 - S565
  • [39] Empagliflozin Improves Kidney Outcomes in Patients With or Without Heart Failure Insights From the EMPA-REG OUTCOME Trial
    Butler, Javed
    Zannad, Faiez
    Fitchett, David
    Zinman, Bernard
    Koitka-Weber, Audrey
    von Eynatten, Maximilian
    Zwiener, Isabella
    George, Jyothis
    Brueckmann, Martina
    Cheung, Alfred K.
    Wanner, Christoph
    CIRCULATION-HEART FAILURE, 2019, 12 (06)
  • [40] Empagliflozin and kidney outcomes in patients with or without heart failure at baseline: insights from the EMPA-REG OUTCOME trial
    Butler, J.
    Zannad, F.
    Fitchett, D.
    Zinman, B.
    Koitka-Weber, A.
    von Eynatten, M.
    Hehnke, U.
    George, J.
    Brueckmann, M.
    Cheung, A. K.
    Wanner, C.
    DIABETOLOGIA, 2018, 61 : S323 - S323
12345